Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Deadly Denials
    • Dead Zone
    • Opioid Settlement Tracking
    • Eleven Minutes
    • Broken Rehab
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Apr 26 2021

Full Issue

Different Takes: Warning Needed On J&J Vaccine; Are Vaccine Passports The Answer To Hesitancy?

Opinion writers tackle these vaccine issues.

The Washington Post: The CDC Was Right To Lift The Pause On The J&J Vaccine But Should Have Warned Younger Women Against Using It

Friday’s vote by an advisory committee to the Centers for Disease and Control Prevention to resume administering the Johnson & Johnson coronavirus vaccine was the right decision, but with a serious mistake: There should be an explicit warning against the vaccine’s use in women under the age of 50. I’m in this group. I’m also a participant in the Johnson & Johnson clinical trial who was told that I’d received the placebo. I then opted to get the Johnson & Johnson vaccine. If I knew then what I know now, I would have chosen the Pfizer or Moderna vaccines instead. (Leana S. Wen, 4/24)

San Francisco Chronicle: Why It's Time To Demand COVID Vaccine Passports In The Bay Area

California’s overwrought vaccine eligibility criteria have fallen away, once-scarce vaccination appointments are proliferating and half of American adults have experienced the oddly joyful soreness of a shot in the arm. It’s a triumph of international science and a success — if a delayed and heavily qualified one — for local, state and federal logistics. A little over a year since the arrival of the novel coronavirus in the Bay Area and the United States, we’re on the brink of protecting a majority of the population from the deadly disease it causes. (4/25)

Bloomberg: Covid-19 Vaccine Rollout Leaves Poor Countries Tragically Behind 

To judge by the headlines, you’d think the most critical immunization issue facing the world is the safety and hesitancy concerns over the AstraZeneca Plc and Johnson & Johnson vaccines. That debate is genuinely important. Still, it shouldn’t distract from the biggest challenge the world will face over the coming months: the grossly unequal distribution of vaccines between rich and poor countries. (Brooke Sample, 4/24)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, July 14
  • Monday, July 13
  • Friday, July 10
  • Thursday, July 9
  • Wednesday, July 8
  • Tuesday, July 7
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF